Author, year

Country

Type of Study

Age in years (Dex, MTP)

Total patients (Dex , MTP)

Mortality (Dex , MTP)

Need for mechanical ventilation (Dex , MTP)

Additional treatment

Ko, et al. (2021) [17]

United States

Retrospective cohort study

57.8 ± 14.9,

56.2 ± 14.1

83, 104

26.5%, 16.4%

43.5%, 45.7%

Remdesevir, plasma therapy, hydroxychloroquine, tocilizumab (tocilizumab only in methylprednisolone cohort)

Ranjbar, et al. (2021) [20]

Iran

Prospective triple blinded RCT

61.3 ± 17.3,

56.2 ± 17.5

42, 44

37.5%, 18.6%

38.1%, 18.2%

None

Pinzón, et al. (2021) [16]

Colombia

Ambispective cohort study

63 (58-69),

64 (60-68)

111, 105

17.1%, 9.5%

19.8%, 2.9%

Antibiotics, colchicine

Fatima, et al. (2020) [18]

Pakistan

Quasi experimental, interventional study

57.91 ± 16.4, 54.86 ± 14.3

35, 65

17.1%, 15.3%

20%, 12.3%

Tocilizumab, antibiotics, plasma therapy

Plessis, et al. (2021) [19]

South Africa

Retrospective observational study

54.5 (46-62), 52.0 (47.5-59)

108, 46

66.7%, 60.9%

63.9%, 50%

None